Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, NOV. 06, 2025 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY TRANSLATING GENETIC INSIGHTS INTO THE DEVELOPMENT OF THERAPIES FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS CHARACTERIZED BY NEURONAL EXCITATION-INHIBITION IMBALANCE, TODAY ANNOUNCED THAT ON NOVEMBER 3, 2025, THE COMPENSATION COMMITTEE OF PRAXIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNIT AWARDS COVERING AN AGGREGATE OF 6,876 SHARES OF ITS COMMON STOCK TO SIX NEW NON-EXECUTIVE EMPLOYEES UNDER THE PRAXIS PRECISION MEDICINES, INC. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN). THE RESTRICTED STOCK UNIT AWARDS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES' ENTERING INTO EMPLOYMENT WITH PRAXIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

PRAXIS PRECISION MEDICINES, INC. ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, OCT. 16, 2025 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY TRANSLATING GENETIC INSIGHTS INTO THE DEVELOPMENT OF THERAPIES FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS CHARACTERIZED BY NEURONAL EXCITATION-INHIBITION IMBALANCE, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 3,025,480 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE PER SHARE OF $157.00 AND, IN LIEU OF SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 318,470 SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $156.9999 PER PRE-FUNDED WARRANT, WHICH EQUALS THE PUBLIC OFFERING PRICE PER SHARE OF THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE OF EACH PRE-FUNDED WARRANT. THE GROSS PROCEEDS FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $525 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES PAYABLE BY PRAXIS. ALL SHARES AND PRE-FUNDED WARRANTS IN THE OFFERING ARE BEING OFFERED BY PRAXIS. IN ADDITION, PRAXIS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 501,592 ADDITIONAL SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT OCTOBER 20, 2025, SUBJECT TO MARKET CONDITIONS AND THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

PRAXIS PRECISION MEDICINES, INC. ANNOUNCES PRICING OF $525 MILLION PUBLIC OFFERING

BOSTON, OCT. 16, 2025 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY TRANSLATING GENETIC INSIGHTS INTO THE DEVELOPMENT OF THERAPIES FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS CHARACTERIZED BY NEURONAL EXCITATION-INHIBITION IMBALANCE, TODAY ANNOUNCED A PROPOSED PUBLIC OFFERING OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PREFUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK. ALL SECURITIES IN THE OFFERING WILL BE OFFERED BY PRAXIS. IN ADDITION, PRAXIS INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN AN AMOUNT UP TO 15% OF THE SHARES OF COMMON STOCK (OR PREFUNDED WARRANTS IN LIEU THEREOF) SOLD IN THE OFFERING AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNT AND COMMISSION.

PRAXIS PRECISION MEDICINES, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

BOSTON, OCT. 02, 2025 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY TRANSLATING GENETIC INSIGHTS INTO THE DEVELOPMENT OF THERAPIES FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS CHARACTERIZED BY NEURONAL EXCITATION-INHIBITION IMBALANCE, TODAY ANNOUNCED THAT ON OCTOBER 1, 2025, THE COMPENSATION COMMITTEE OF PRAXIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNIT AWARDS COVERING AN AGGREGATE OF 4,200 SHARES OF ITS COMMON STOCK TO THREE NEW NON-EXECUTIVE EMPLOYEES UNDER THE PRAXIS PRECISION MEDICINES, INC. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN). THE RESTRICTED STOCK UNIT AWARDS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES' ENTERING INTO EMPLOYMENT WITH PRAXIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

MENLO PARK, CALIF.--(BUSINESS WIRE)--RECODE THERAPEUTICS, A CLINICAL-STAGE GENETIC MEDICINES COMPANY USING TISSUE-SPECIFIC DELIVERY TO POWER THE NEXT WAVE OF MRNA AND GENE CORRECTION THERAPEUTICS, TODAY ANNOUNCED THE CLOSE OF OVER $29 MILLION IN ADDITIONAL FINANCING. THE COMPANY ALSO REPORTED EXPANDED SUPPORT FROM THE CYSTIC FIBROSIS FOUNDATION (CF FOUNDATION) AND A NEW RESEARCH COLLABORATION WITH PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX). WITH CONTINUED SUPPORT FROM ORGANIZATIONS LIKE T.

RECODE THERAPEUTICS ANNOUNCES OVER $29 MILLION IN ADDITIONAL FINANCING TO ADVANCE GENETIC MEDICINES PIPELINE AND PROVIDES CORPORATE UPDATE

NEW YORK , SEPT. 13, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF PRAXIS PRECISION MEDICINES, INC. ("PRAXIS" OR THE "COMPANY") (NASDAQ: PRAX).

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF PRAXIS PRECISION MEDICINES, INC. - PRAX

NEW YORK , SEPT. 8, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF PRAXIS PRECISION MEDICINES, INC. ("PRAXIS" OR THE "COMPANY") (NASDAQ: PRAX).

BOSTON, MASS., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES , INC. (NASDAQ: PRAX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY TRANSLATING GENETIC INSIGHTS INTO THE DEVELOPMENT OF THERAPIES FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS CHARACTERIZED BY NEURONAL EXCITATION-INHIBITION IMBALANCE, TODAY ANNOUNCED THAT PRAXIS' MANAGEMENT WILL BE ATTENDING AND PRESENTING IN THREE UPCOMING INVESTOR CONFERENCES:

PRAXIS PRECISION MEDICINES TO PARTICIPATE IN SEPTEMBER INVESTOR CONFERENCES

BOSTON, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- PRAXIS PRECISION MEDICINES, INC. (NASDAQ: PRAX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY TRANSLATING GENETIC INSIGHTS INTO THE DEVELOPMENT OF THERAPIES FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS CHARACTERIZED BY NEURONAL EXCITATION-INHIBITION IMBALANCE, TODAY ANNOUNCED THAT ON SEPTEMBER 2, 2025, THE COMPENSATION COMMITTEE OF PRAXIS' BOARD OF DIRECTORS GRANTED RESTRICTED STOCK UNIT AWARDS COVERING AN AGGREGATE OF 6,238 SHARES OF ITS COMMON STOCK TO EIGHT NEW NON-EXECUTIVE EMPLOYEES UNDER THE PRAXIS PRECISION MEDICINES, INC. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN). THE RESTRICTED STOCK UNIT AWARDS WERE GRANTED AS INDUCEMENTS MATERIAL TO THE EMPLOYEES' ENTERING INTO EMPLOYMENT WITH PRAXIS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NEW YORK , SEPT. 3, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF PRAXIS PRECISION MEDICINES, INC. ("PRAXIS" OR THE "COMPANY") (NASDAQ: PRAX).

NEW YORK, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF PRAXIS PRECISION MEDICINES, INC. (PRAXIS OR THE COMPANY) (NASDAQ: PRAX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

Praxis Precision Medicines, Inc.

PRAX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Praxis Precision Medicines, Inc.

PRAX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PRAX